4 completed, 1 terminated. 5 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 5 | Completed 4, Terminated 1 |
Follow Drug Abuse: new trials by email Literature Review of Drug Abuse trials Research Report on Drug Abuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER), Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER) - Opioid-Related Disorders, Opiate Addiction | Phase 4 | Terminated | Member Companies of the Opioid PMR Consortium | 44 | 2016-09-14 | 2019-11-06 |
| Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED) buprenorphine, buprenorphine/naloxone - Opiate-related Disorders, Opiate Dependence | Phase 4 | Completed | Indivior Inc. | 60 | 2007-07-01 | 2023-03-20 |
| Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Services will be provided at one site, Services remain dispersed; i.e., not centralized to one-location or provider. - Buprenorphine, HIV | Phase 4 | Completed | Yale University | 60 | 2005-08-01 | 2015-07-24 |
| Improving Hepatitis C Treatment in Injection Drug Users Pegylated Interferon and Ribavirin, Psychosocial, On-site (MMT Clinic) HCV evaluation and treatment - Hepatitis C, Liver Diseases | Phase 4 | Completed | State University of New York - Upstate Medical University | 111 | 2003-09-01 | 2013-04-24 |
| Reinforcement-Based Treatment and Abstinence-Contingent Housing for Drug Abusers Reinforcement Based Treatment - Drug Abuse | Phase 4 | Completed | National Institute on Drug Abuse (NIDA) | 463 | 2002-08-01 | 2017-01-11 |
Substance-Related Disorders (5) · Opioid-Related Disorders (3) · Alcoholism (1) · Digestive System Diseases (1) · Hepatitis C (1) · Liver Diseases (1) · Narcotic-Related Disorders (1) · Patient Acceptance of Health Care (1) · Patient Compliance (1)
Chemically-Induced Disorders (5) · Mental Disorders (5) · Narcotic-Related Disorders (2) · Alcohol-Related Disorders (1) · Behavior (1) · Blood-Borne Infections (1) · Communicable Diseases (1) · Flaviviridae Infections (1) · Health Behavior (1) · Hepatitis (1) · Hepatitis, Viral, Human (1) · Infections (1) · RNA Virus Infections (1) · Treatment Adherence and Compliance (1) · Virus Diseases (1)
Buprenorphine (1) · Buprenorphine, Naloxone Drug Combination (1) · Ribavirin (1) · Therapeutics (1)
Indivior Inc. (1) · Member Companies of the Opioid PMR Consortium (1) · National Institute on Drug Abuse (NIDA) (1) · State University of New York - Upstate Medical University (1) · Yale University (1)
United States (4)
Frederick Altice, MD (1) · Maxine Stitzer, Ph.D. (1) · Steven L Batki, MD (1)
R01DA016764 (1)